Skip to contentN
Northwest Biotherapeutics Inc
N
NWBONorthwest Biotherapeutics Inc Q3 2023 · 10-Q
Revenue$406.00K$406.00K+97.1% vs Q3 2022 Net Income-$18.58M-$18.58MN/M vs Q3 2022 EPS Diluted-$0.02-$0.02N/M vs Q3 2022 Operating Income-$13,825,000N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Northwest Biotherapeutics Inc · CIK 1072379 · Engraved from SEC EDGAR
derived
Free Cash Flowderived-$14,356,000— Margins · derivedOperating margin-3405.2%+4176.4 pt vs Q3 2022
Net margin-4576.4%+11371.2 pt vs Q3 2022
ended Sep 30, 2023 · filed Nov 9, 2023 · 40 d after period end